Bridgeway Capital Management LLC Has $15.84 Million Position in Pediatrix Medical Group, Inc. $MD

Bridgeway Capital Management LLC increased its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 14.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 740,280 shares of the company’s stock after acquiring an additional 93,488 shares during the quarter. Bridgeway Capital Management LLC owned about 0.86% of Pediatrix Medical Group worth $15,835,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Guggenheim Capital LLC acquired a new position in Pediatrix Medical Group in the 4th quarter valued at $747,000. AQR Capital Management LLC grew its holdings in Pediatrix Medical Group by 4.7% in the 4th quarter. AQR Capital Management LLC now owns 551,823 shares of the company’s stock valued at $11,803,000 after buying an additional 24,633 shares in the last quarter. Cetera Investment Advisers grew its holdings in Pediatrix Medical Group by 48.4% in the 4th quarter. Cetera Investment Advisers now owns 16,808 shares of the company’s stock valued at $360,000 after buying an additional 5,481 shares in the last quarter. Lazard Asset Management LLC grew its holdings in Pediatrix Medical Group by 34.3% in the 4th quarter. Lazard Asset Management LLC now owns 138,358 shares of the company’s stock valued at $2,959,000 after buying an additional 35,349 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Pediatrix Medical Group by 4.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 86,572 shares of the company’s stock valued at $1,852,000 after buying an additional 3,790 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Pediatrix Medical Group Price Performance

Shares of MD stock opened at $23.56 on Thursday. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.45. Pediatrix Medical Group, Inc. has a twelve month low of $11.84 and a twelve month high of $24.99. The company has a market cap of $1.93 billion, a P/E ratio of 11.44 and a beta of 0.69. The business has a fifty day simple moving average of $22.58 and a 200 day simple moving average of $21.70.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.The business had revenue of $476.20 million during the quarter, compared to the consensus estimate of $465.83 million. During the same period in the prior year, the company earned $0.33 EPS. Pediatrix Medical Group’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 2.1 EPS for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In related news, Director Shirley A. Weis sold 36,028 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total transaction of $855,665.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on MD shares. Mizuho set a $24.00 price objective on Pediatrix Medical Group in a report on Friday, May 8th. Truist Financial upped their price objective on Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a report on Monday, April 13th. UBS Group upped their price objective on Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Jefferies Financial Group reiterated a “buy” rating and set a $27.00 target price on shares of Pediatrix Medical Group in a research report on Monday, April 20th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Pediatrix Medical Group currently has an average rating of “Hold” and a consensus target price of $22.50.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.